X4 Pharmaceuticals Inc Post-EHA Corporate Update Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Stephen Willey - Stifel - Analyst : Hey, good morning. Thanks for taking the questions and congratulations on the update. Can (technical difficulty) I guess how an infection event was defined in this trial? And then, I guess when you speak to the 75% (technical difficulty) reduction statistic?

Question: Stephen Willey - Stifel - Analyst : I'm sorry, yes, can you hear me any better, Paula?

Question: Stephen Willey - Stifel - Analyst : Okay, sorry about that. So, can you just remind us how an infection event was defined in the trial? And when you speak to the 75% reduction in cutaneous warts that was observed, how many patients are included within that reduction statistic?

Question: Stephen Willey - Stifel - Analyst : I guess what proportion of patients again?

Question: Stephen Willey - Stifel - Analyst : Okay, thank you. And just lastly, I think there's going to be a manuscript that was previously mentioned of this -- of this Phase 2 experience. I guess is that something that we should expect in the near term? And within that manuscript, should we anticipate seeing any additional data points such as supportive care like G-CSF that might have been required by patients throughout the open-label extension phase? Thanks.

Question: Joel Beatty - Citi - Analyst : Hi, congrats on the data. The first question is on the annualized infection rate, a followup question for me, you're talking about before. Any thoughts on what could be causing that trend of continuing to decrease overtime? And then the second question is not just on this point but overall, can you talk a little bit about the consistency of results across patients and what you're seeing there? Thanks.

Question: Leland Gershell - Oppenheimer - Analyst : Good morning. Thanks for taking my questions. Just a question on the time above threshold, my slides were coming just a little bit choppy. This may have been shown but I just wanted to ask what the range was in terms of what you saw on TAT for the patients in the open-label? Thanks.

Question: Leland Gershell - Oppenheimer - Analyst : Okay, thanks. And then also just a question with the current program you have with Invitae, I wanted to ask if you're able to share any rates of positive confirmation of WHIM syndrome in those who were getting tested? Thank you. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: Laura Christianson - Cowen - Analyst : Good morning. Thanks for taking my question. I guess this might also be coming with the manuscript, but I am curious how many patients were taking G-CSF in the one year prior to enrollment and how that factors into your thoughts about the reductions in infection that you're seeing?

Question: Mayank Mamtani - B. Riley FBR - Analyst : Good morning, team. Thanks for taking my question and congrats on the update. Can you just maybe call out what is the incremental update on -- I know it's a longer followup but relative to the ASH abstract in 2018, could you maybe just talk to the infection rate that was reported at that time, the improvement per patient per month? I'm just curious relative to that incremental what did we learn today and how does that inform you as you think about the longer term impact of mavorixafor in WHIM syndrome patients? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: Mayank Mamtani - B. Riley FBR - Analyst : Great. And can you just remind us -- I'm sure this would be in the manuscript, I believe there were two patients at the time that had some antibiotics use systemic, at this update, has there been more use of antibiotics on the trial?

Question: Mayank Mamtani - B. Riley FBR - Analyst : Okay, great. And just last question, just could you maybe comment on some of the feedback from the -- especially the investigator community folks obviously participating some of -- in the study, in the Phase 3 study and how that could influence also enrollment and things like that?

Question: RK Ramakanth - H.C. Wainwright - Analyst : Thank you. Congratulations for multiple times I guess. A couple of quick questions. Most of my questions had been answered but I just want to kind of understand a little bit on the wart reduction. So in the presentation, you said it's 75% reduction in the number of cutaneous warts. So how do you define in the sense, do they -- that particular patient which -- whose hands we see, is that region defined and you'd say that, within this region how many warts have gone down from baseline to now or during the treatment period, is that how it is looked back? And also is there a thinking about or quantification about the quality of the wart and the size of the wart? And the third piece within the wart question is do you also look out for any new warts you obtained during the treatment period and the followup period, not in the defined area where you just started off at the baseline but outside of that defined period -- defined area?

Question: RK Ramakanth - H.C. Wainwright - Analyst : Just that's -- yes, the second question is like if the size of the wart could reduce but not (multiple speakers) --

Question: RK Ramakanth - H.C. Wainwright - Analyst : Qualitative.

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Good morning. Thanks for taking my question and congrats on the [trial] which seem to be maturing very nicely. But based on that time-dependent improvements in infection rates mentioned, I'm just curious if that 21-week for example patients are responding more robustly in terms of keeping their neutrophil counts above the threshold versus that five weeks for example.

Question: Zegbeh Jallah - ROTH Capital Partners - Analyst : Yes, I was just trying to see if there were any changes in terms of time on how robustly patients were responding to the same dose for example. So, perhaps at week 21, if they responded a lot better to the same dose than they did at week five.